1625 related articles for article (PubMed ID: 8509225)
1. Disialoganglioside GD2 anti-idiotypic monoclonal antibodies.
Cheung NK; Canete A; Cheung IY; Ye JN; Liu C
Int J Cancer; 1993 May; 54(3):499-505. PubMed ID: 8509225
[TBL] [Abstract][Full Text] [Related]
2. A novel O-acetylated ganglioside detected by anti-GD2 monoclonal antibodies.
Ye JN; Cheung NK
Int J Cancer; 1992 Jan; 50(2):197-201. PubMed ID: 1730513
[TBL] [Abstract][Full Text] [Related]
3. Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival.
Cheung NK; Cheung IY; Canete A; Yeh SJ; Kushner B; Bonilla MA; Heller G; Larson SM
Cancer Res; 1994 Apr; 54(8):2228-33. PubMed ID: 8174131
[TBL] [Abstract][Full Text] [Related]
4. Induction of IgG antibodies by an anti-idiotype antibody mimicking disialoganglioside GD2.
Sen G; Chakraborty M; Foon KA; Reisfeld RA; Bhattacharya-Chatterjee MB
J Immunother; 1998 Jan; 21(1):75-83. PubMed ID: 9456440
[TBL] [Abstract][Full Text] [Related]
5. Ganglioside GD2 specificity of monoclonal antibodies to human neuroblastoma cell.
Saito M; Yu RK; Cheung NK
Biochem Biophys Res Commun; 1985 Feb; 127(1):1-7. PubMed ID: 2579648
[TBL] [Abstract][Full Text] [Related]
6. Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes.
Riemer AB; Förster-Waldl E; Brämswig KH; Pollak A; Zielinski CC; Pehamberger H; Lode HN; Scheiner O; Jensen-Jarolim E
Eur J Immunol; 2006 May; 36(5):1267-74. PubMed ID: 16568495
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation in nonhuman primates of murine monoclonal anti-idiotype antibody that mimics the disialoganglioside GD2.
Sen G; Chakraborty M; Foon KA; Reisfeld RA; Bhattacharya-Chatterjee M
Clin Cancer Res; 1997 Nov; 3(11):1969-76. PubMed ID: 9815586
[TBL] [Abstract][Full Text] [Related]
8. The idiotype (Id) cascade in mice elicited the production of anti-R24 Id and anti-anti-Id monoclonal antibodies with antitumor and protective activity against human melanoma.
Ramos AS; Parise CB; Travassos LR; Han SW; de Campos-Lima PO; de Moraes JZ
Cancer Sci; 2011 Jan; 102(1):64-70. PubMed ID: 21070480
[TBL] [Abstract][Full Text] [Related]
9. Generation of a human anti-idiotypic antibody that mimics the GD2 antigen.
Saleh MN; Stapleton JD; Khazaeli MB; LoBuglio AF
J Immunol; 1993 Sep; 151(6):3390-8. PubMed ID: 8376782
[TBL] [Abstract][Full Text] [Related]
10. Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases.
Zhang H; Zhang S; Cheung NK; Ragupathi G; Livingston PO
Cancer Res; 1998 Jul; 58(13):2844-9. PubMed ID: 9661900
[TBL] [Abstract][Full Text] [Related]
11. Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study.
Kushner BH; Kramer K; Modak S; Cheung NK
J Clin Oncol; 2011 Mar; 29(9):1168-74. PubMed ID: 21343563
[TBL] [Abstract][Full Text] [Related]
12. Targeting of ganglioside GD2 monoclonal antibody to neuroblastoma.
Cheung NK; Neely JE; Landmeier B; Nelson D; Miraldi F
J Nucl Med; 1987 Oct; 28(10):1577-83. PubMed ID: 3655911
[TBL] [Abstract][Full Text] [Related]
13. Syngeneic anti-idiotypic monoclonal antibodies to an anti-NeuGc-containing ganglioside monoclonal antibody.
Vázquez AM; Pérez A; Hernández AM; Macías A; Alfonso M; Bombino G; Pérez R
Hybridoma; 1998 Dec; 17(6):527-34. PubMed ID: 9890708
[TBL] [Abstract][Full Text] [Related]
14. Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma.
Heiner JP; Miraldi F; Kallick S; Makley J; Neely J; Smith-Mensah WH; Cheung NK
Cancer Res; 1987 Oct; 47(20):5377-81. PubMed ID: 3115567
[TBL] [Abstract][Full Text] [Related]
15. Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency.
Vincent M; Bessard A; Cochonneau D; Teppaz G; Solé V; Maillasson M; Birklé S; Garrigue-Antar L; Quéméner A; Jacques Y
Int J Cancer; 2013 Aug; 133(3):757-65. PubMed ID: 23354868
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibody 3F8 recognises the neural cell adhesion molecule (NCAM) in addition to the ganglioside GD2.
Patel K; Rossell RJ; Pemberton LF; Cheung NK; Walsh FS; Moore SE; Sugimoto T; Kemshead JT
Br J Cancer; 1989 Dec; 60(6):861-6. PubMed ID: 2481486
[TBL] [Abstract][Full Text] [Related]
17. Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma.
Kramer K; Gerald WL; Kushner BH; Larson SM; Hameed M; Cheung NK
Med Pediatr Oncol; 2001 Jan; 36(1):194-6. PubMed ID: 11464881
[TBL] [Abstract][Full Text] [Related]
18. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses.
Bolesta E; Kowalczyk A; Wierzbicki A; Rotkiewicz P; Bambach B; Tsao CY; Horwacik I; Kolinski A; Rokita H; Brecher M; Wang X; Ferrone S; Kozbor D
Cancer Res; 2005 Apr; 65(8):3410-8. PubMed ID: 15833876
[TBL] [Abstract][Full Text] [Related]
19. Oral (1-->3),(1-->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma.
Cheung NK; Modak S
Clin Cancer Res; 2002 May; 8(5):1217-23. PubMed ID: 12006541
[TBL] [Abstract][Full Text] [Related]
20. Molecular characterization of the anti-idiotypic immune response of a relapse-free neuroblastoma patient following antibody therapy: a possible vaccine against tumors of neuroectodermal origin?
Uttenreuther-Fischer MM; Krüger JA; Fischer P
J Immunol; 2006 Jun; 176(12):7775-86. PubMed ID: 16751426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
